Home  |  Contact

UniProtKB/Swiss-Prot P02647: Variant p.Glu160Lys

Apolipoprotein A-I
Gene: APOA1
Variant information

Variant position:  160
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamate (E) to Lysine (K) at position 160 (E160K, p.Glu160Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (E) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism:  Genetic variations in APOA1 can result in APOA1 deficiency and are associated with low levels of HDL cholesterol [MIM:107680].
Additional information on the polymorphism described.

Variant description:  In Norway.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  160
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  267
The length of the canonical sequence.

Location on the sequence:   RQKVEPLRAELQEGARQKLH  E LQEKLSPLGEEMRDRARAHV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHV

Gorilla                       RQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHV

                              RQKVAPLGSELREGARQKLQELQEKLSPLAEELRDRARTHV

Rhesus macaque                RQKVEPLRAELHEGTRQKLHELHEKLSPLGEEVRDRARAHV

Chimpanzee                    RQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHV

Mouse                         RQKVAPLGAELQESARQKLQELQGRLSPVAEEFRDRMRTHV

Rat                           RQKLEPLGTELH----KNAKEMQRHLKVVAEEFRDRMRVNA

Pig                           RQKMAPLGAEFREGARQKVQELQEKLSPLAEELRDRLRAHV

Bovine                        RQKVAPLGEEFREGARQKVQELQDKLSPLAQELRDRARAHV

Rabbit                        RQKVEPLGAELRESARQKLTELQEKLSPLAEELRDSARTHV

Chicken                       RQRLTPVAQELKELTKQKVELMQAKLTPVAEEARDRLRGHV

Zebrafish                     REKLEPVFQEYSALNRQNAEQLRAKLEPLMDDIRKAFESNI

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 19 – 267 Proapolipoprotein A-I
Chain 25 – 267 Apolipoprotein A-I
Chain 25 – 266 Truncated apolipoprotein A-I
Repeat 145 – 166 5
Region 68 – 267 10 X approximate tandem repeats
Turn 159 – 164


Literature citations

Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted.
Rall S.C. Jr.; Weisgraber K.H.; Mahley R.W.; Ogawa Y.; Fielding C.J.; Utermann G.; Haas J.; Steinmetz A.; Menzel H.J.; Assmann G.;
J. Biol. Chem. 259:10063-10070(1984)
Cited for: VARIANT NORWAY LYS-160;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.